Cannabis Investments

Sarah Martin has Multiple Sclerosis and, while the British government sells British manufactured cannabis medicines to other countries, it continues to deny it to it’s own patients. Countries such as Germany and Denmark purchase Sativex, made by GW Pharmaceuticals, as pain and spasm relieving medicine. Sativex is a cannabis tincture, effectively a new strain of SKUNK in a bottle. The tax payer should not be asked to support the growth of a benign plant and manufacture of a medicine that can be grown for free. Basic common sense and medical guidance will allow the patient to treat themselves safely in their own homes. By the way, I’m voting for the Liberal Democrats as they have a more sensible and ultimately humane approach to drug policy.

Sarah Martin has Multiple Sclerosis and, while the British government sells British manufactured cannabis medicines to other countries, it continues to deny it to it’s own patients. Countries such as Germany and Denmark purchase Sativex, made by GW Pharmaceuticals, as pain and spasm relieving medicine. Sativex is a cannabis tincture, effectively a new strain of SKUNK in a bottle. The tax payer should not be asked to support the growth of a benign plant and manufacture of a medicine that can be grown for free. Basic common sense and medical guidance will allow the patient to treat themselves safely in their own homes. Please visit my SarahSoulFood page to see more of my activism. www.youtube.com Any comments against the police will be removed! By the way, I’m voting for the Liberal Democrats as they have a more sensible and ultimately humane approach to drug policy.

The industry analysis specialist’s new report, “Neuropathic Pain – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products.

Analyzed that there are over 111 molecules in various stages of the pipeline. Vimpat, Qutenza, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war.

Scope of the Report

The scope of the report includes:

Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.

Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc., AstraZeneca.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to Buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global neuropathic pain market landscape? – Identify, understand and capitalize.

For more information,please visit:

http://www.aarkstore.com/reports/Neuropathic-Pain-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40530.html

It was announced earlier this week that GW Pharmaceuticals, a pharmaceutical company that has been the topic of conversation in the medical field due to its cannabis derived products, is soon to have their very first product on sale to the public if all goes according to plan. Last week this company announced that they had received sound approval from officials in the UK as well as Spain to say that there was no reason why their pharmaceutical medication should not be available on the market. The medication that this company has developed is called Sativex, a pharmaceutical drug that will treat spasticity in individuals suffering from Multiple Sclerosis.

The UK regulators for this drug, which is not yet available to the public, say that all is safe with the drug and that there is no compromise on quality, even though the drug has derivative of cannabis in it. This is the first time that a medication will be sold that includes direct derivative of cannabis. The GW pharmaceutical corporation says that the plant is supposedly grown in areas around London but the company is keeping mum about its exact location. Much controversy has surrounded this product for obvious reasons and when employees have been questioned about their opinion, they admit that it is their clinical job and that they do not hold biased opinions.

The selling of this controversial drug will payout a large sum of money to Bayer Pharmaceuticals owing to the fact that they own shares in the company. Another partner, a Spanish pharmaceutical company, will also get a considerable payout from the approval of the drug. Pharmacovigilance will let this drug be sold not only in the UK but also other European countries.

This is not the end of the line for the drug however, there still has to be more testing and if all goes according to plan, the drug will be officially sold in three approximately three months. It seems that three months will not be much more of a delay for GW Pharmaceuticals as there have been numerous setbacks in the testing, manufacturing and approving of the drug that the company has had to overcome.

If all goes according to plan, this controversial pharmaceutical company will extend their use of cannabis from Savitex to other drugs which will include pain medication used for patients suffering from cancer. The release of this drug will really change the face of regulatory affairs in pharmaceuticals and who knows what next drug could contain cannabis?

medicalcannabis.com